Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ KLX Energy Services Announces Preliminary Results of Subscription Rights Offering (PR Newswire) +++ KLX ENERGY Aktie +3,68%

TERUMO Aktie

 >TERUMO Aktienkurs 
13.145 EUR    +3.5%    (TradegateBSX)
Ask: 13.205 EUR / 379 Stück
Bid: 12.69 EUR / 395 Stück
Tagesumsatz: 16 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
TERUMO Aktie über LYNX handeln
>TERUMO Performance
1 Woche: -2,6%
1 Monat: -12,2%
3 Monate: +3,2%
6 Monate: +10,8%
1 Jahr: -11,3%
laufendes Jahr: +1,8%
>TERUMO Aktie
Name:  TERUMO CORP.
Land:  Japan
Sektor:  Gesundheit
ISIN/ Wkn:  JP3546800008 / 867003
Symbol/ Ticker:  TUO (Frankfurt)
Kürzel:  FRA:TUO, ETR:TUO, TUO:GR
Index:  Nikkei225
Profil:  Terumo Corporation, a leading global medical device company, specializes in the development, production, and distribution of healthcare solutions primarily in the cardiovascular and vascular area. Established in 1921 and headquartered in Tokyo, Japan..
>Volltext..
Marktkapitalisierung:  18356.46 Mio. EUR
Unternehmenswert:  18759.62 Mio. EUR
Umsatz:  6398.47 Mio. EUR
EBITDA:  1629.61 Mio. EUR
Nettogewinn:  889.17 Mio. EUR
Gewinn je Aktie:  0.6 EUR
Schulden:  2105.19 Mio. EUR
Liquide Mittel:  1700.71 Mio. EUR
Operativer Cashflow:  1474 Mio. EUR
Bargeldquote:  0.76
Umsatzwachstum:  4.24%
Gewinnwachstum:  20.35%
Dividende je Aktie:  0.17 EUR
Dividendenrendite:  1.34%
Dividendenschätzung:  1.63%
Div. Historie:  30.03.26 - 0.081819154€
29.09.25 - 0.085464€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  TERUMO
Letzte Datenerhebung:  25.09.26
>TERUMO Kennzahlen
Aktien/ Unternehmen:
Aktien: 1475.1 Mio. St.
Frei handelbar: 89.57%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 31185
Umsatz/Mitarb.: 0.2 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 40.31%
Bewertung:
KGV: 20.62
KGV lG: 17.29
KUV: 2.75
KBV: 2.04
PEG-Ratio: 0.62
EV/EBITDA: 11.51
Rentabilität:
Bruttomarge: 53.03%
Gewinnmarge: 13.9%
Operative Marge: 16.9%
Managementeffizenz:
Gesamtkaprendite: 7.88%
Eigenkaprendite: 10.85%
>TERUMO Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Stoffwechselerkrankungen (Diabetes/ Adipositas), Herz-Kreislauf- Behandlung/ Kardiologie
 
14.09.26 - 13:54
Bora Biologics Selected to Develop, Scale Up, and Supply RAPClot Protein Supporting Terumo′s Japan Launch of RAPClot Blood Collection Tubes (Accesswire)
 
Successful scale-up to commercial production supports long-term supply agreement for Q Sera's patented RAPClot technology SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Bora Biologics, a U.......
07.08.26 - 10:12
Terumo GAAP EPS of ¥47.73, revenue of ¥311.81B; updates FY 2207 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.08.26 - 10:00
Terumo Q1 Results Improve; Ups Annual Profit Outlook On Refund Of U.S. Tariffs, Settlement Proceeds (AFX)
 
TOKYO (dpa-AFX) - Terumo Corporation (TRUMF, 4543.T), a Japanese medical technology company, on Friday reported a surge in net earnings, helped by increased revenue, reflecting the positive perfor......
21.07.26 - 13:00
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway (Zacks)
 
Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth....
20.07.26 - 22:00
4 Medical Products Stocks Poised to Win Despite Industry Headwinds (Zacks)
 
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient....
29.06.26 - 14:03
Terumo Interventional Systems Announces First Procedure Using Its OPUSWAVE® Dual Sensor Imaging System in the United States (PR Newswire)
 
Marks a major milestone in expanding access to this next-generation intravascular imaging technology, helping physicians make more informed decisions across a wide range of coronary interventions Addresses the need to balance the deep vessel visualization of IVUS with the high-resolution......
20.05.26 - 21:54
Terumo übertrifft Gewinnprognosen für Q4 2025 – Aktie legt nachbörslich stark zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
15.05.26 - 20:36
Terumo GAAP EPS of ¥74.25, revenue of ¥831.5B (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.05.26 - 12:01
Earnings Call: Terumo erzielt Rekordumsatz im Geschäftsjahr 2025 (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
15.05.26 - 10:12
Terumo Corporation Expects Annual Earnings, Revenue To Improve Amidst Volatile Global Trends (AFX)
 
TOKYO (dpa-AFX) - Terumo Corporation (TRUMF, 4543.T), a Japanese medical technology company, said on Friday that it expects a rise in annual earnings and revenue.The company said: 'In the fiscal y......
15.05.26 - 09:54
Terumo Corporation Full Year Profit Rises (AFX)
 
TOKYO (dpa-AFX) - Terumo Corporation (TRUMF) released earnings for its full year that Increased, from the same period last yearThe company's bottom line totaled JPY135.914 billion, or JPY92.12 per......
07.05.26 - 14:03
Endologix Announces Appointment of Steve Deitsch to Board of Directors (Business Wire)
 
SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the appointment of Steve Deitsch to its Board of Directors. Mr. Deitsch brings more than 25 years of global leadership experience across medtech and the broader healthcare sector. He currently serves as Chief Executive Officer of Caristo Diagnostics, a global leader in AI technology for cardiovascular disease and a spinout from the University of Oxford. Previously, Mr. Deitsch was Chief Financial Officer of OrganOx, where he led the company's 2025 sale to Terumo Corporation for $1.5 billion, representing the largest spinout exit in the University of Oxford's history. “Having worked closely with Steve while on the OrganOx board, I've seen firsthand his strategic insight, financial acumen, and ability to execute complex transactions,” said John Liddicoat, President and CEO of Endologix. “He ...
15.04.26 - 17:06
Terumo Corporation Joins the Healthcare Plastics Recycling Council (Accesswire)
 
NORTHAMPTON, MA / ACCESS Newswire / April 15, 2026 / The Healthcare Plastics Recycling Council (HPRC) is pleased to welcome Terumo Corporation, a global medical technology company that develops, ma......
08.04.26 - 23:24
Japan′s Terumo steps up medical device R&D in Costa Rica (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
19.03.26 - 10:42
Tata Elxsi Announces the Launch of a Global Offshore Development Center (ODC) for Terumo Corporation (PR Newswire)
 
PUNE, India, March 19, 2026 /PRNewswire/ -- Tata Elxsi, a global leader in design and technology services, and Terumo Corporation, a global medical innovation company, today inaugurated the 'Terumo–Tata Elxsi Offshore Development Center'. This dedicated center will support the development......
13.02.26 - 14:51
Terumo reports Q3 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.26 - 10:24
Terumo Corporation Profit Rises In Nine Months (AFX)
 
TOKYO (dpa-AFX) - Terumo Corporation (TRUMF) announced earnings for its nine months that Increased, from last yearThe company's bottom line came in at JPY109.547 billion, or JPY74.25 per share. Th......
13.02.26 - 10:12
Terumo Corp.: Rekordumsatz im dritten Quartal, Aktie gibt wegen Inflations- und Zollsorgen nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.26 - 08:30
Terumo Reports Higher Earnings In 9-Month; Raises FY26 Guidance (AFX)
 
TOKYO (dpa-AFX) - Terumo Corp. (TRUMY, TRUMF, 4543.T), a Japanese medical technology company, on Friday reported higher net income in the nine-month period ended December 31, 2025, compared with t......
06.01.26 - 16:36
Terumo Launches SurTract Safety Syringe In US Market (AFX)
 
TOKYO (dpa-AFX) - Terumo Medical Corp. (4543.T) announced on Tuesday that it will be launching its SurTract Safety Syringe in the U.S. This syringe comes with SafeR passive safety technology creat......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ästhetische Vorschriften existieren für mich nicht. Was auf mich wirkt, wirkt. - Theodor Fontane
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!